Meta-analysis of randomized controlled trials for the association of incretins with fractures risk in patients with type 2 diabetes / 中华内分泌代谢杂志
Chinese Journal of Endocrinology and Metabolism
; (12): 844-854, 2020.
Article
em Zh
| WPRIM
| ID: wpr-870109
Biblioteca responsável:
WPRO
ABSTRACT
Objective:
To conduct a meta-analysis of clinical data to investigate the relationship between incretins and fracture in order to provide individualized hypoglycemic agents for type 2 diabetic patients with osteoporosis.Methods:
PubMed, Embase, Web of Science, and Cochrane databases were searched up to January 1, 2018 for randomized controlled trials(RCTs)and the relationship between incretins and fracture was explored by meta-analysis.Results:
The meta-analysis showed that the use of incretin was not associated with fracture risk compared with placebo or other positive hypoglycemic agents( OR 0.972, 95% CI 0.876-1.079). But in the subgroup analysis, 100 mg/d sitagliptin( OR 0.495, 95% CI 0.304-0.806)or 1.8 mg/d liraglutide( OR 0.621, 95% CI 0.413-0.933)reduced fracture risk.Conclusions:
Meta-analysis shows no increase in the incidence of fracture events after the use of incretin. 100 mg/d sitagliptin or 1.8 mg/d liraglutide may exert protective effects on bone metabolism. However, the included data are from the reports of fracture adverse reactions in RCT studies, and large-scale clinical studies are needed to confirm these findings.
Texto completo:
1
Base de dados:
WPRIM
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Systematic_reviews
Idioma:
Zh
Revista:
Chinese Journal of Endocrinology and Metabolism
Ano de publicação:
2020
Tipo de documento:
Article